Introduction
============

The Gram-positive bacterium *Listeria monocytogenes* (*Lm*) is an opportunistic, intracellular pathogen that may cause severe, food-borne infections in high-risk groups such as immunocom promised persons, elderly people and pregnant women ([@B6]). *Lm* is able to survive and replicate in a wide range of environments including soil, various food products, and different niches inside its human host ([@B6]; [@B35]; [@B5]; [@B8]). In order to adapt to these changing conditions, *L. monocytogenes* possesses 15 complete two-component systems ([@B37]) and a number of regulatory circuits ([@B11]). The accessory gene regulator (*agr*) locus encodes one of these systems and has been shown to be involved in biofilm formation, virulence and survival in the environment ([@B1]; [@B28]; [@B27]; [@B34]).

The prototype *agr* system was described for *S. aureus* and consists of the four gene operon *agrBDCA* ([@B20]). Of the four proteins encoded by the *agr* operon, AgrB is a membrane-bound peptidase that cleaves and processes the *agrD*-derived propeptide at the C-terminus, catalyzes formation of a thiolactone ring with a central cysteine, and, in combination with the signal peptidase SpsB, effects export and release of the active autoinducing peptide (AIP). Upon accumulation in the extracellular space, this AIP activates a two-component system consisting of AgrC (receptor-histidine kinase) and AgrA (response regulator). Expression of the operon is driven by the P~II~ promoter upstream of *agrB* and is subject to autoregulation via AgrA. Target genes of the staphylococcal *agr* system are either directly regulated by AgrA or by a regulatory RNAIII transcribed in the opposite direction from the P~III~ promoter adjacent to P~II~ ([@B32]).

Homologous *agr* systems have been identified in a number of Gram-positive microorganisms including streptococci, clostridia, lactobacilli, *Bacillus sp.*, and *Enterococcus faecalis* ([@B39]). The effects of *agr* regulation are pleiotropic. In *S. aureus*, the *agr* system regulates a wide range of genes involved in biofilm formation, virulence, and immune evasion ([@B26]; [@B32]). The *agr* system of *Lactobacillus plantarum* is involved in regulation of cell morphology and adhesion to glass surfaces ([@B30]; [@B7]). Similar to the staphylococcal system, the *agr*-like *fsr* system of *E. faecalis* and the *agr* system of *Lm* are involved in regulation of biofilm formation and virulence ([@B1]; [@B28]; [@B27]; [@B4]). Moreover, in *Lm* more than 650 genes are directly or indirectly regulated by the *agr* system as shown by transcriptional profiling of an *agrD* deletion mutant ([@B27]). This suggests that *agr* systems represent rather global regulatory mechanisms.

Despite similarities on protein level, genetic organization, and phenotypic traits regulated, known *agr* systems differ regarding their mechanisms of target gene regulation. While in staphylococci, a significant number of *agr*-dependent genes are regulated by RNAIII ([@B32]), no information on RNAIII transcripts are available in other organisms. In *E. faecalis* and *Lm*, the genetic information upstream of the *agr* operon differs from that of staphylococci in that the preceding gene is transcribed in the same direction as the *agr* genes and no putative P~III~ promoters have been identified ([@B24]; [@B1]). Moreover, despite extensive bioinformatic approaches or transcriptional profiling a regulatory RNAIII has not been identified in *Lm* ([@B15]; [@B33]; [@B17]; [@B38]). This suggests that in *Lm* (and *E. faecalis*) target genes are regulated by AgrA and/or other transcriptional regulators affected by AgrA-dependent regulation. However, it can not be excluded that the AIP signals through other two-component system besides AgrCA.

Structural information of AIPs is available only for a limited number of species. In *S. aureus*, four *agr* specificity groups with different AIPs varying in size from 7 to 9 amino acids (aa) are known ([@B20]). Similarly, three *agr* specificity groups exist in *S. epidermidis* with AIPs of 8--12 aa ([@B22]; [@B21]). The AIP of *S. intermedius* and *S. lugdunensis* are 9 and 7 aa in size, respectively ([@B12]; [@B13]). Outside the genus *Staphylococcus*, AIPs have been characterized for *E. faecalis* (11 aa), *L. plantarum* (5 aa), and *C. acetobutylicum* (6 aa) ([@B19]; [@B30]; [@B29]). Most of the known AIPs contain a thiolactone ring formed by the 5 C-terminal aa. Exceptions are the AIPs of *C. acetobutylicum* and *E. faecalis*, which have ring structures consisting of 6 and 9 aa, respectively ([@B19]; [@B29]). Another common feature is a central cysteine, which is replaced by a serine in some cases, required for thiolactone ring formation.

For staphylococci, *E. faecalis* and *Lm*, a contribution of the *agr* system to virulence gene regulation has been demonstrated and *agr*-deficient mutants are attenuated ([@B27]; [@B32]; [@B4]). Consequently, interference with *agr* signaling was proposed as a therapeutic approach ([@B10]). Of note, the specificity of the interaction between the AIP and its cognate receptor AgrA has been used to device improved strategies by fusing the AIP to a bacteriocin to induce lysis of the targeted bacteria ([@B25]). The structure of the native AIP of *Lm* has not been elucidated so far. With the present study, we aim closing this gap in order to further elucidate the components and mechanisms of the *agr* autoregulatory circuit of *Lm* and to facilitate future studies on strategies to interfere with cell--cell communication of this important human pathogen.

Materials and Methods {#s1}
=====================

Bacterial Strains and Culture Conditions
----------------------------------------

All strains and plasmids used in this study are listed in **Table [1](#T1){ref-type="table"}**. *L. monocytogenes* was generally incubated in Brain Heart Infusion broth (BHI, Oxoid Ltd) at 30°C. *E. coli* strains were grown in lysogeny broth (LB). For solid media, 15 g/l agar were added to the broth before autoclaving. Antibiotics were added if necessary. Where appropriate, kanamycin was used at a final concentration of 50 (for *E. coli* strains) and 15 μg/ml chloramphenicol were used for both species. For *Lm* strains carrying a chromosomal copy of pPL2 derivatives chloramphenicol was used at 7 μg/ml.

###### 

Bacterial strains and plasmids used in the present study.

  Strain/plasmid                                     Characteristics                                                                                      Reference/source
  -------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------
  **Strains**                                                                                                                                             
  *Escherichia coli* DH10B                           Cloning host                                                                                         Thermo Fisher Scientific
  *E. coli* BL21 DE3                                 Used for protein overexpression                                                                      New England Biolabs
  *E. coli* BL21 DE3 pET29a\_*agrB*                  IPTG-inducible expression of *agrB*, Kan^r^                                                          This study
  *E. coli* BL21 DE3 pET29a\_*agrBD*                 IPTG-inducible expression of *agrBD*, Kan^r^                                                         This study
  *Listeria monocytogenes* EGD-e                                                                                                                          [@B2]
  *L. monocytogenes* Δ*agrD*                         In-frame deletion of *agrD* in strain EGD-e                                                          [@B27]
  *L. monocytogenes*Δ*agrD*::pIMK2*agrD*             pIMK2*agrD* integrated into the tRNA^Arg^ locus in the EGD-e chromosome, Kan^r^                      [@B27]
  *L. monocytogenes* EGD-e::pPL2*lux*P~II~           pPL2*luxABCDE*P~II~ integrated into the tRNA^Arg^ locus in the EGD-e chromosome, Cm^r^               This study
  *L. monocytogenes* EGD-e *ΔagrD*::pPL2*lux*P~II~   pPL2*lux*P~II~ integrated into the tRNA^Arg^ locus in the EGD-e*ΔagrD* chromosome, Cm^r^             This study
  *L. monocytogenes* EGD-e *ΔagrD* pNZ44*agrBD*      Strain with constitutive, P~44~-driven expression of *agrB* and *agrD*, Cm^r^                        This study
  **Plasmids**                                                                                                                                            
  pPL2*lux*                                          Site-specific integrative vector to study promotor activity in *L. monocytogenes*, Cm^r^             [@B3]
  pPL2*lux*P~II~                                     Site-specific integrative vector for P~II~ promoter activity analysis, Cm^r^                         This study
  pNZ44                                              Plasmid for constitutive gene expression driven from the lactococcal promoter P~44~                  [@B16]
  pNZ44*agrBD*                                       Plasmid for constitutive P~44~-driven expression of *agrB* and *agrD* in *L. monocytogenes*, Cm^r^   This study
  pET29a(+)                                          Plasmid for strong IPTG inducible expression in *E. coli*, Kan^r^                                    Merck Millipore
  pET29a\_*agrB*                                     IPTG-inducible expression of *agrB* in *E. coli*, Kan^r^                                             This study
  pET29a\_*agrBD*                                    IPTG-inducible expression of *agrBD* in *E. coli*, Kan^r^                                            This study

Generation of Recombinant Strains
---------------------------------

Primers used for cloning or sequencing purposes are listed in **Table [2](#T2){ref-type="table"}**. To study transcriptional activity of the *agr* operon, the P~II~ promoter upstream of *agrB* ([@B28]) was amplified with Phusion^®^ polymerase (Thermo Fisher Scientific) using primers PII_fwd_SalI and PII_rev and chromosomal DNA of *Lm* EGD-e wildtype (WT) as template. The obtained PCR fragment was digested with *Sal*I and cloned in frame in front of the luciferase reporter into *Sal*I/*Swa*I-cut pPL2*lux* ([@B3]). The ligation mix was transformed into *E. coli* ElectroMax^TM^ DH10B (Thermo Fisher Scientific), and the resulting plasmid pPL2*lux*P~II~ was verified by restriction analysis and amplification of the cloned P~II~ promoter using primers PII_fwd_SalI and luxA_rev with subsequent Sanger sequencing of the PCR fragment by a commercial service provider (Eurofins, Germany). The plasmid was transformed into electrocompetent *Lm* EGD-e WT or Δ*agrD* ([@B27]) as described previously ([@B18]) creating *Lm* EGD-e::pPL2*lux*P~II~ and Δ*agrD*::pPL2*lux*P~II~. In both strains, successful chromosomal integration of pPL2*lux*P~II~ at the correct site (tRNA^Arg^) was verified using primers PL95 and PL102 ([@B14]).

###### 

Primers used in this study.

  Name              Sequence                                 Reference/source
  ----------------- ---------------------------------------- ------------------
  PII_fwd_SalI      CTGATGTCGACCTTCAAACAGAACAAGACG           This study
  PII_rev           CAACTAATTCACCTCCACTAATATTTTACAACG        This study
  luxA_rev          TACCTCTGTTTGAGAAAATTGGGGAGG              This study
  PL95              ACATAATCAGTCCAAAGTAGATGC                 Lauer, 2002
  PL102             TATCAGACCTAACCCAAACCTTCC                 Lauer, 2002
  NZagrBD-fwd       AATTCCATGGGTAATTTTACTGCAAAAGTCCC         This study
  NZagrBD-rev       GCATCGAGCTCTTATTTATTTTCGTTTTTTTC         This study
  NZ-conf_fwd       CCATACAGGAGAAGGGACGATAGCAA               This study
  NZ_colony_rev     CCTTGAGCCAGTTGGGATAGAGC                  This study
  agrBD_NdeI_fwd    GGAATTCCATATGAGTAATTTTACTGCAAAAGTCCC     This study
  agrBD_BamHI_rev   CGCGGATCCATTAATCCTCCACTGTCTAAAATATCTAT   This study

For homologous overexpression of *agrBD*, a PCR fragment containing both genes was amplified using primers NZagrBD_fwd and NZagrBD_rev and chromosomal DNA of *Lm* EGD-e as template. The PCR product was digested with *Nco*I and *Sac*II and ligated as exact transcriptional fusion to the constitutive P~44~ promoter into *Nco*I/*Sac*II digested pNZ44 ([@B16]) to yield pNZ44*agrBD*. The product was transformed into *E. coli* DH10B. Clones were screened for plasmid containing the correct insert by PCR using primers NZ-confirm_fwd and NZ_colony_rev and sequencing of the PCR product. The correct plasmid as well as the empty vector (pNZ44) were transformed in electrocompetent *Lm* Δ*agrD* generated as described previously ([@B18]).

For heterologous AIP production, *agrBD* or *agrB* alone were amplified using primer pairs agrBD_NdeI_fwd/agrBD_BamHI_rev and chromosomal DNA of *Lm* EGD-e WT or Δ*agrD*. Following restriction with *Nde*I and *BamH*I both PCR products were ligated into *Nde*I/*BamH*I digested pET29a(+) (Merck Millipore). This fuses the PCR products to the T7 promoter creating pET29a\_*agrB* and pET29a\_*agrBD*, respectively. Both plasmids were verified for correct cloning by restriction analysis and Sanger sequencing of inserts.

Luciferase Reporter Assays
--------------------------

For luciferase reporter assays, growth experiments were performed in white 96-well microtiter plates with transparent bottom (BRANDplates^®^ pureGrade^TM^ S). A single colony was inoculated into BHI and grown over night (o/N; i.e., approx. 16 h). Following o/N growth, cultures were diluted to an optical density at 600 nm (OD~600~) of 0.01 in fresh, sterile BHI. For co-cultivation of AIP producer and reporter strains, o/N cultures of both strains were used to inoculate BHI medium to a OD~600~ of 0.01 and then mixed at a 1:1 ratio. 200 μl aliquots of this mix were transferred into individual wells of the microtiter plates (each condition in triplicates). Plates were incubated at 30°C in a Tecan Infinite M200 plate reader and OD~600~ and luminescence intensity were measured every hour.

Synthetic Peptides
------------------

Synthetic peptides were purchased from Peptide Protein Research Ltd (UK) in lyophilized form with \>70% purity. Peptides were reconstituted in dimethyl sulfoxide (DMSO) at 2 mM and stored at -20°C until further use. For experiments, these stocks were diluted as appropriate in 25% (v/v) DMSO in phosphate-buffered saline (PBS) to give the final concentrations as indicated. To test the effect of peptides on P~II~ activity, reporter strains (*Lm* EGD-e::pPL2*lux*P~II~ or Δ*agrD*::pPL2*lux*P~II~) were grown o/N and diluted to an OD~600~ of 0.01 in fresh BHI. 180 μl aliquots were distributed in 96 well microtiter plates (each condition in triplicate) and incubated at 30°C for 2 h. At this stage, 20 μl of diluted peptides were added to obtain the indicated final concentrations (5 nM--50 μM) and plates were incubated at 30°C in a Tecan Infinite M200 plate reader with hourly OD~600~ and luminescence intensity measurements.

AIP Production in *E. coli*
---------------------------

For heterologous AIP production, pET29a\_*agrB* or pET29a\_*agrBD* were transformed into *E. coli* BL21(DE3) (New England Biolabs) and transformants were selected on LB agar containing kanamycin. Four single colonies were streaked onto two LB agar plates containing kanamycin with or without 1 mM isopropyl β-[D]{.smallcaps}-1-thiogalactopyranoside (IPTG). A clone showing good growth in the absence of IPTG but reduced growth in its presence was selected and a single colony was inoculated into 5 ml of LB medium and grown o/N on a rotary shaker at 37°C. Using the o/N culture, 500 ml LeMaster and Richards minimal medium ([@B23]) containing 50 mM glucose were inoculated to a final OD~600~ of 0.1 and incubated on a rotary shaker at 37°C to an OD~600~ of 0.8. At this stage, expression was induced by addition of 1 mM ITPG. Following incubation under the same conditions for an additional 2 h, bacterial cells were pelleted via centrifugation (3000 × g, 30 min and 4°C) and supernatants were collected, filter sterilized, frozen in liquid nitrogen and lyophilized. Lyophilized samples were stored at -20°C until further analysis by LC--MS/MS.

LC--MS/MS Analysis
------------------

The lyophilized supernatants of recombinant *E. coli* strains were reconstituted in a 25:35:35:5 H~2~O:Isopropanol:CH~3~CN:HCOOH mixture and diluted 1:10 in H~2~O. 5 μl were injected into a reverse-phase column with corresponding guard column (Aeris^TM^ PEPTIDE 3.6u XB-C18 150 × 2.1 mm, Security Guard^TM^ ULTRA 2 × 2.1 mm guard column, Phenomenex). A constant flow rate of 0.4 ml/min was applied. Mobile phase A consisted of water with 0.2% (v/v) formic acid and mobile phase B was acetonitrile with 0.2% (v/v) formic acid. Elution program was: isocratic hold at 5% B for 5 min followed by a linear gradient from 5 to 45% B over 80 min. After each sample, the column was washed with 90% B for 10 min and equilibrated at starting conditions. Data was obtained in positive auto MS/MS mode on an Agilent 6540 Accurate-Mass Quadrupole (LC-Q-TOF/MS) with ESI Jet Stream Technology using the following conditions: drying gas flow rate of 10 l/min with a gas temperature of 250°C, nebulizer with 40 lb per square inch gauge, sheath gas flow rate of 10 l/min, sheath gas temperature of 300°C, capillary voltage of 4000 V, and fragmentor voltage of 170 V. The collision energy was set by formula with 4.5 slope and 10 offset. Data analysis was performed using Mass Hunter Workstation Software (Ver.B.05.519.0, Agilent Technologies) and the "Find compounds by formula" algorithms. Synthetic peptides were analyzed using the same conditions as the recombinant peptides expressed in *E. coli* to compare retention time, accurate mass and fragmentation patterns.

Invasion Assay
--------------

Invasion of *Lm* into Caco-2 cells was tested using a standard gentamycin protection assay essentially as described previously ([@B27]). Briefly, Caco-2 cells were cultured in DMEM supplemented with 10% (v/v) fetal calf serum (FCS), 10 mM [L]{.smallcaps}-glutamine, 1% (v/v) penicillin/streptomycin and 1% (v/v) non-essential amino acids (NEAA) at 37°C and a 5% CO~2~ atmosphere. Cells were seeded to a density of 2 × 10^5^ cells per well in a 24 well plate and cultivated to a monolayer for 4 days. One day prior to the experiment, culture media without antibiotics was added. A fresh o/N culture of the indicated bacterial strains was diluted 1:10 in 10 ml fresh BHI and grown to mid-exponential phase (OD~600~ = 0.8). Where appropriate, peptide R5T0 was added (5 μM final concentration). Bacteria were pelleted and diluted in DMEM containing 10 mM [L]{.smallcaps}-glutamine and 1% NEAA to 10^8^ colony forming units per ml (cfu/ml) (OD~600~ = 0.5). 1 ml of this suspension was added to Caco-2 cells in quadruplicates (MOI = 100). Cells were incubated for 1 h to allow invasion of bacteria. To kill remaining extracellular bacteria, cells were washed once with PBS and 1 ml DMEM containing 10 μg/ml gentamicin (Gibco^®^) was added to the cells. After 1 h of incubation, cells were washed twice with PBS, lysed with ice-cold water and cfu/ml were determined by plating serial dilutions on BHI agar.

Statistical Analysis
--------------------

All experiments were conducted in at least three biological replicates. Results were analyzed by Student's *t*-test or ANOVA with Bonferroni post-test analysis to correct for multiple comparisons using GraphPad Prism (version 6) as indicated in figure legends and Supplementary Data Sheet 1. Differences between different strains or conditions were considered statistically significant at *p* \< 0.05.

Results
=======

P~II~-Activity in *Lm* EGD-e
----------------------------

P~II~ promoter activity was analyzed in *Lm* EGD-e::pPL2*lux*P~II~ and Δ*agrD*::pPL2*lux*P~II~ during growth in BHI medium at 30°C (**Figure [1A](#F1){ref-type="fig"}**). No differences in growth or final OD~600~ were observed between the two strains ruling out an effect of growth on luciferase activity. In the WT background, a significant increase in P~II~-dependent luciferase activity was observed during exponential growth with a peak in late exponential phase. By contrast, no luminescence above background could be detected for the *agrD*-deficient strain throughout the experiment. This suggests that the AIP is required for transcriptional activity of P~II~.

![**Growth (OD~600~) and luminescence (relative luminescence units; RLU) of *Lm* EGD-e::pPL2*lux*P~II~ (WT*lux*) or Δ*agrD*::pPL2*lux*P~II~ (Δ*lux*) grown alone **(A)** or in co-culture **(B)** with Δ*agrD* pNZ44*agrBD* (ΔBD+), Δ*agrD* pNZ44 (Δ-), or EGD-e pNZ44 (WT-).** Values are mean ± standard deviation of three independent experiments. Statistical analysis of RLU values was performed by Student's *t*-test and results are provided in Supplementary Data Sheet 1.](fmicb-07-00989-g001){#F1}

AIPs are usually secreted into the extracellular environment. In order to confirm that the AIP of *Lm* is acting as an extracellular peptide, similar growth experiments were conducted using co-incubation of AIP producer and reporter strains in different combinations (**Figure [1B](#F1){ref-type="fig"}**). As expected, the *agrD*-deficient reporter strain showed no P~II~ activity when incubated with *Lm* EGD-e Δ*agrD*. However, high levels of luminescence were observed using the same reporter strain in combination with *Lm* Δ*agrD* pNZ44*agrBD*, a Δ*agrD* derivative expressing *agrBD* from the P44 promoter on pNZ44. Luminescence in this setup was significantly higher compared to co-cultures of the WT reporter with the *agrD* deletion mutant or the *agrD*-deficient reporter strain with *Lm* EGD-e pNZ44 (i.e., the empty vector control) suggesting that AIP levels produced by *Lm* Δ*agrD* pNZ44*agrBD* are higher than that of the WT.

P~II~ Activation by Synthetic AIP Candidates
--------------------------------------------

Upon several attempts we were unable to identify the active AIP in supernatants of *Lm* EGD-e WT or the AIP overproducing strain Δ*agrD* pNZ44*agrBD* grown in either BHI or modified Welshimer's broth. Sequence alignment of AIPs with a resolved structure, revealed that most AIPs consist of a 5 aa thiolactone ring with N-terminal tail varying from 0 to 7 aa (**Figure [2A](#F2){ref-type="fig"}**). Using this information, a range of peptides based on the AgrD sequence of *Lm* EGD-e were synthesized consisting of a thiolactone ring of 4--6 aa and an N-terminal tail of 0--5 aa (**Figure [2B](#F2){ref-type="fig"}**). The effect of these peptides on P~II~-driven luciferase activity was tested using the reporter strains *Lm* EGD-e::pPL2*lux*P~II~ and Δ*agrD*::pPL2*lux*P~II~. At 5 μM, none of the peptides had a measurable effect on growth of the reporter strains (Supplementary Figures [S1A,B](#SM1){ref-type="supplementary-material"}). The peptide R5T0 consisting of a 5 aa thiolactone ring with no N-terminal tail slightly increased P~II~-driven luminescence in the WT reporter strain during the first 4 h of the experiment (**Figure [3A](#F3){ref-type="fig"}**). However, at later stages luminescence was comparable to the control, i.e., reporter without peptide. Interestingly, some of the tested peptides (R5T1, R5T2, R5T4, and R5T5) significantly inhibited luminescence of the WT reporter strain. More importantly, some of the peptides (R5T0, R5T1, R5T4, and R5T5) induced luminescence by the Δ*agrD* reporter strain (**Figure [3B](#F3){ref-type="fig"}**). The most potent inducer of P~II~ activity was the peptide R5T0, i.e., a cyclic pentapeptide with the amino acid sequence Cys-Phe-Met-Phe-Val (CFMFV). At concentration of 5 and 50 μM, R5T0 also induced luminescence above control levels during the first 4 h in the WT reporter (**Figure [3C](#F3){ref-type="fig"}**) and for up to 7 h in the *agrD*-deficient reporter (**Figure [3D](#F3){ref-type="fig"}**). This suggests that the most likely candidate for the native AIP of *Lm* EGD-e is the peptide R5T0.

![**(A)** Amino acid sequences of AgrD propetides with known structure compared with the AgrD sequence of *Listeria monocytogenes*. **(B)** Structure of synthetic cyclic peptides tested for autoinducing activity in *L. monocytogenes*. Amino acid residues of the native **(A)** or synthetic **(B)** peptides involved in thiolactone ring formation are labeled in green, those found in the N-terminal tails in yellow. The central cysteine or serine is marked by a red letter.](fmicb-07-00989-g002){#F2}

![**Luminescence (RLU) of *Lm* EGD-e::pPL2*lux*P~II~**(A,C)** or Δ*agrD*::pPL2*lux*P~II~**(B,D)** grown in the presence of different synthetic peptides (**A,B**; peptide concentration: 5 μM) or peptide R5T0 at the indicated concentrations **(C,D)**.** Values are mean ± standard deviation of three independent experiments. Statistical analysis of RLU values was performed by ANOVA and Bonferroni test to correct for multiple comparisons and results are provided in Supplementary Data Sheet 1.](fmicb-07-00989-g003){#F3}

The Synthetic AIP Restores the Invasion Defect of *Lm ΔagrD*
------------------------------------------------------------

Deletion of Δ*agrD* and thus lack of a functional AIP results in reduced promoter activity of virulence factors and attenuated virulence ([@B27]). In order to check if R5T0 is not only able to induce P~II~ activity but also functionally complement the Δ*agrD* mutant, invasion assays were performed with *Lm* EGD-e Δ*agrD* grown in the presence and absence of R5T0 (**Figure [4](#F4){ref-type="fig"}**). As observed previously, deletion of *agrD* results in reduced invasion into Caco-2 intestinal epithelial cells and this defect was genetically complemented by integration of pIMK2*agrD*, i.e., a plasmid for constitutive expression of *agrD* ([@B27]). More importantly, growth in the presence of 5 μM R5T0 completely restored invasion of *Lm* EGD-e Δ*agrD* to WT levels.

![**Invasion of *Lm* EGD-e (WT), EGD-e Δ*agrD* (Δ*agrD*), or EGD-e Δ*agrD*::pIMK2*agrD* (Comp) into Caco-2 cells.** Bacteria were grown either in the absence (black bars) or presence of 5 μM peptide R5T0. Values are colony forming units per well (cfu/well) and are mean ± standard deviation of three independent experiments. Statistical analysis was performed by comparing all strains for a given condition (with or without peptide) by ANOVA. Bonferroni post tests were used to adjust *p* values for multiple comparisons.](fmicb-07-00989-g004){#F4}

Heterologous Production of the *Lm* AIP in *E. coli*
----------------------------------------------------

In a further approach to identify the AIP of *Lm*, the *agrBD* genes were expressed in *E. coli* using the IPTG-inducible pET29a system. Using LC--MS, a prominent signal was identified in supernatants of an induced culture of *E. coli* BL21 pET29a\_*agrBD* (**Figure [5A](#F5){ref-type="fig"}**) with a mass of 627.2549 (**Figure [5B](#F5){ref-type="fig"}**). This signal was absent in the non-induced culture or supernatant of a control strain only expressing *agrB* (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). In order to confirm the identity of the overexpressed peptide, analysis of the P~II~-activating synthetic peptide R5T0 was performed. Interestingly, the chromatogram of R5T0 yielded two peaks in close vicinity (**Figure [5A](#F5){ref-type="fig"}**). Both peaks correspond to peptides with identical mass and fragmentation pattern (**Figure [5B](#F5){ref-type="fig"}**). However, the different retention times and peak areas indicate that the two peaks represent stereoisomers or conformational isomers at different concentrations.

![**(A)** Extracted ion chromatograms performed on culture supernatant of *Escherichia coli* BL21 DE3 pET29a\_*agrBD* after induction with IPTG (BD+; upper panel) and the synthetic peptide R5T0 (lower panel; R5T0 molecular formula: C~31~H~41~N~5~O~5~S~2~). **(B)** Mass spectrometry fragmentation spectra for chromatographic peaks with retention times of 61.2 and 63.9 min (marked with a box in **A**). **(C,D)** Structure and assignment of fragments detected in MS/MS spectra to fragments of R5T0.](fmicb-07-00989-g005){#F5}

The peptide present in the supernatant of *E. coli* BL21 pET29a\_*agrBD* and both peaks of R5T0 had almost identical global masses (**Figure [5B](#F5){ref-type="fig"}**). Moreover, all three peptides showed highly similar fragmentation patterns (**Figure [5B](#F5){ref-type="fig"}**) and several signals of the MS/MS spectra correspond to fragments of R5T0 at a mass accuracy better than 2 ppm (**Table [3](#T3){ref-type="table"}**; for corresponding structures see **Figures [5C,D](#F5){ref-type="fig"}**). These results clearly indicate that the listerial AIP is a cyclic pentapeptide with the amino acid sequence CFMFV forming a thiolactone ring, i.e., the structure of the synthetic peptide R5T0.

###### 

Mass-charge-ratios (*m/z*) of peptide fragments detected by MS/MS and difference to the *m/z* calculated according to the formula of the corresponding R5T0 fragment.

  Fragment     Formula                  *m/z* (calculated)   *m/z* (measured)^a^   Difference (ppm)   Difference (mDa)
  ------------ ------------------------ -------------------- --------------------- ------------------ ------------------
  *b*~FV~      C~26~H~33~N~4~O~4~S~2~   529.19377            529.1933              -0.9               -0.47
  *b*~FV~-CO   C~25~H~33~N~4~O~3~S~2~   501.19886            501.1994              1.1                0.54
  *b*~MF~      C~17~H~24~N~2~S~2~       382.12536            382.1256              0.6                0.24
  *b*~FM~      C~12~H~15~N~2~O~2~S      251.08487            251.0843              -2.3               -0.57
  *b*~FM~-CO   C~11~H~15~N~2~OS         223.08996            223.0898              -0.7               -0.16

a
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m/z

are derived from the MS/MS analysis shown in

Figure
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Specificity of the *Lm* AIP
---------------------------

Known AIPs differ greatly in sequence, length and structure among species and even strains (**Figure [2A](#F2){ref-type="fig"}**) and different AIPs of *S. aureus* display cross-inhibition ([@B12]). Similar to the AIP of *Lm*, the AIP of *L. plantarum* is a cyclic pentapeptide yet with a different sequence ([@B30]). Further experiments were performed to test if P~II~ activation is specific for the *Lm* AIP or if the *L. plantarum* AIP is also able to activate P~II~ (**Figure [6](#F6){ref-type="fig"}**). As observed in the previous experiments, R5T0 slightly enhanced P~II~-driven luciferase activity in *Lm* EGD-e::pPL2*lux*P~II~ (**Figure [6A](#F6){ref-type="fig"}**) and was a potent inducer of P~II~ activity in the AIP-negative reporter strain *Lm* EGD-e Δ*agrD*::pPL2*lux*P~II~. By contrast, in both reporter strains the *L. plantarum* AIP had no effect on P~II~ activity.

![**Luminescence (RLU) of *Lm* EGD-e::pPL2*lux*P~II~**(A)** or Δ*agrD*::pPL2*lux*P~II~**(B)** grown in the presence of the AIP of *Lm* (Lm; i.e., synthetic peptide R5T0) or *L. plantarum* (Lpl).** As controls, bacteria were grown without peptides (control). Values are mean ± standard deviation of three independent experiments. Statistical analysis of RLU values was performed by ANOVA and Bonferroni test to correct for multiple comparisons and results are provided in Supplementary Data Sheet 1.](fmicb-07-00989-g006){#F6}

Discussion
==========

Signaling peptides, also referred to as AIPs, are produced by a wide range of Gram-positive microorganisms ([@B39]) and serve various purposes ([@B31]). The best studied AIP system is the *agr* locus of *S. aureus* and homologous systems have been identified in a variety of Gram-positives ([@B39]). In *S. aureus*, the *agr* system is a rather global regulatory circuit affecting a large number of genes and different phenotypic traits ([@B32]). Similarly, deletion of *agrD* in *Lm* affects more than 600 genes and phenotypically affects biofilm formation and virulence *in vitro* and *in vivo* ([@B28]; [@B27]). However, while absence of *agr* signaling is linked with enhanced biofilm formation of *S. aureus* ([@B36]), *agr* mutants of *Lm* display reduced biofilm formation under the conditions monitored ([@B28]; [@B27]).

Previous studies have already indicated that, like the staphylococcal system, the *Lm agr* locus is subject to positive autoregulation involving a diffusible factor, probably the *agrD*-encoded AIP involved in regulation. Transcription levels of the *agr* operon were greatly reduced in *agr*-deficient *Lm* mutants ([@B28]; [@B27]; [@B9]). Also, the biofilm defect of a Δ*agrD* mutant was complemented when bacteria were grown in the reconstituted culture supernatants of the WT or in the presence of small amounts of WT bacteria ([@B27]). The presented results further strengthen the hypothesis that *agrD* encodes a secreted AIP that positively regulates the *agr* system of *Lm*. In the Δ*agrD* mutant, no activity of the *agr* promoter could be observed (**Figure [1A](#F1){ref-type="fig"}**) and promoter activity was restored when the *agrD*-deficient reporter strain was co-cultured with a strain carrying a plasmid for constitutive expression of *agrBD* (**Figure [1B](#F1){ref-type="fig"}**).

The presented results provide further evidence that, in *Lm, agrD* actually encodes the propeptide, which is processed released into the extracellular environment where it acts as an AIP. Moreover, our data suggests that the native AIP is a cyclic pentapeptide R5T0 consisting of the amino acids (from N- to C-terminus) Cys, Phe, Met, Phe, Val. A peptide with this structure was found in the culture supernatant of a recombinant *E. coli* strain expressing AgrBD (**Figure [5](#F5){ref-type="fig"}**) and a synthetic peptide with identical structure was able to potently induce activity of the P~II~ promoter of the *agr* system (**Figure [3](#F3){ref-type="fig"}**) and to functionally complement the invasion defect in a Δ*agrD* mutant (**Figure [4](#F4){ref-type="fig"}**).

Induction of luciferase activity in the Δ*agrD* reporter upon co-cultivation with the AIP producing WT strain (**Figure [1B](#F1){ref-type="fig"}**) indicates that at least some of the AIP must be present in culture supernatants. However, we were unable to identify the native peptide in supernatants of *Lm* EGD-e grown in complex media (brain heart infusion) or modified Welshimer's broth. This may be explained by the high levels of peptides in brain heart infusion, which makes identification impossible by LC--MS/MS. In modified Welshimer's broth *Lm* only grows to low final optical densities and thus any secreted peptide will also be present at low concentrations especially when subject to positive autoregulation and fully induced only at high cell densities. Further studies will be needed to quantify actual AIP concentrations in culture supernatants and the threshold required to activate PII and target gene regulation.

Interestingly, four different synthetic peptides with a five-membered thiolactone ring and varying tail length had inhibitory activity on the *agr* promoter in the WT reporter strain, which itself is able to produce the native AIP. Since *agr* mutants of *Lm* display attenuated virulence ([@B1]; [@B27]), this suggests that these peptides are antagonists of the native AIP and may represent a potential supplementary or alternative therapeutic approach as proposed for *S. aureus* and other pathogens ([@B10]). Interestingly, they also exhibited P~II~ activation in the Δ*agrD* reporter to varying degrees. This may indicate that these peptides compete with R5T0 or the native AIP for binding to the receptor but their affinity and/or activity is lower. Thus, of the four candidate peptides, the best antagonist of the native AIP is probably R5T2, which efficiently blocks P~II~ activity in the WT but activates luminescence inly marginally in the mutant reporter.

A striking difference between the *agr* systems of *S. aureu*s and *Lm* is the structural diversity of the AIPs. Within the species *S. aureus*, four specificity groups of strains with different AIP are found and these groups show cross-inhibition ([@B20]). By contrast, the AgrD propeptides of the genus *Listeria* are rather conserved and the species *Lm, L. innocua, L. ivanovii, L. welshimeri, L. seeligeri*, and *L. marthii* have identical (predicted) AIP sequences (Supplementary Figure [S3A](#SM1){ref-type="supplementary-material"}) suggesting cross-reactivity. Moreover, phylogenetic analysis based on 16S rRNA gene sequences reveals that *Listeria sp.* that share identical AIP sequences form a cluster that separates from the other species indicating that they are more closely related (Supplementary Figure [S3B](#SM1){ref-type="supplementary-material"}).

With the exception of *C. acetobutylicum*, phylogenetic trees calculated using concatenate AgrA, AgrB, AgrC, and AgrD sequences are in line with trees inferred from 16S sequences ([@B39]). This suggests that *agr* systems are generally inherited vertically. It has been proposed that *C. acetobutylicum*, whose AgrD sequence is almost identical to that of *Listeriaceae*, is the only known case of horizontal transfer of an *agr* system ([@B39]). Further experimental data comparing the *Lm* AIP with the AIP of *L. plantarum*, which also consist of a five cyclic pentapeptide although with different aa composition, indicates that the *Lm agr* system is specific for the AIP of those *Listeria* sp. that share a conserved AgrD sequence but does not respond to the cyclic pentapeptide AIPs of other organisms. This also suggests that intervention strategies based on antagonistic peptides targeting the *agr* systems of *Lm* (and other organisms) are specific for organisms with identical AIPs.

In summary, the presented data shows that the *agrD* of *Lm* EGD-e encodes a secreted peptide consisting of a five-membered thiolactone ring, which has autoinducing activity. Moreover, the identification of several synthetic peptides with antagonistic activity proposes a potential option to treat *Lm* infections or inhibit biofilm formation as suggested by others previously.
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